Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Proqr Therapeutics (PRQR)

Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 218,902
  • Shares Outstanding, K 81,680
  • Annual Sales, $ 7,050 K
  • Annual Income, $ -30,430 K
  • EBIT $ -29 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.24
  • Price/Sales 30.93
  • Price/Cash Flow N/A
  • Price/Book 7.94

Options Overview Details

View History
  • Implied Volatility 208.27% ( -64.80%)
  • Historical Volatility 94.46%
  • IV Percentile 88%
  • IV Rank 26.01%
  • IV High 722.08% on 01/22/24
  • IV Low 27.68% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 385
  • Volume Avg (30-Day) 199
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 4,278
  • Open Int (30-Day) 4,246

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.27 +21.41%
on 12/16/24
3.97 -30.73%
on 11/29/24
-0.92 (-25.07%)
since 11/27/24
3-Month
1.74 +58.05%
on 10/02/24
4.62 -40.48%
on 10/17/24
+0.92 (+50.27%)
since 09/27/24
52-Week
1.61 +70.81%
on 07/03/24
4.62 -40.48%
on 10/17/24
+0.74 (+36.82%)
since 12/27/23

Most Recent Stories

More News
ProQR Therapeutics Appoints Dr. Peter Beal as Chief ADAR Scientist to Advance RNA Editing Platform

ProQR Therapeutics appoints Dr. Peter Beal as Chief ADAR Scientist to enhance RNA editing technology development.Quiver AI SummaryProQR Therapeutics has appointed Dr. Peter Beal, a prominent expert in...

PRQR : 2.75 (+2.61%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 2.75 (+2.61%)
Best Momentum Stocks to Buy for October 2nd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 2:BRF S.A. BRFS: This meat processing company has a Zacks Rank #1 and witnessed the Zacks...

BRFS : 4.03 (-2.42%)
SNAX : 0.6352 (-4.06%)
PRQR : 2.75 (+2.61%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 2.75 (+2.61%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 2.75 (+2.61%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 2.75 (+2.61%)
ProQR: Q1 Earnings Snapshot

ProQR: Q1 Earnings Snapshot

PRQR : 2.75 (+2.61%)
Why Shares of ProQR Therapeutics Dropped on Wednesday

The clinical-stage biotech released fourth-quarter and full-year earnings.

LLY : 783.37 (-1.36%)
PRQR : 2.75 (+2.61%)
Lilly and ProQR to Expand RNA Editing Collaboration

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and...

LLY : 783.37 (-1.36%)
PRQR : 2.75 (+2.61%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 2.75 (+2.61%)

Business Summary

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the...

See More

Key Turning Points

3rd Resistance Point 2.83
2nd Resistance Point 2.78
1st Resistance Point 2.73
Last Price 2.75
1st Support Level 2.63
2nd Support Level 2.58
3rd Support Level 2.53

See More

52-Week High 4.62
Fibonacci 61.8% 3.47
Fibonacci 50% 3.12
Fibonacci 38.2% 2.76
Last Price 2.75
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar